Dean M. Wingerchuk, M.D.

Closed for Enrollment

• A Combination Trial of Copaxone Plus Estriol in Relapsing-Remitting Multiple Sclerosis (Estriol in MS) Scottsdale/Phoenix, Ariz.

  This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone injections in all subjects. The primary outcome measure is a reduction in relapses.

• A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica (NMO) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing neuromyelitis optica.

• A Prospective Observational Study of Maintenance Plasma Exchange (PLEX) for Neuromyelitis Optica Spectrum Disorders (MultiPLEX Study) (MultiPLEX) Scottsdale/Phoenix, Ariz., Rochester, Minn.

  Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly used as a rescue therapy for NMO relapses but ongoing, regular PLEX procedures (maintenance PLEX) is sometimes used to prevent relapses. This observational registry will record feasibility, tolerability, safety, and preliminary efficacy data regarding maintenance PLEX for NMO.

• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica (NMO) (PREVENT) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to assess the effectiveness and safety of eculizumab treatment as compared to a placebo in patients with relapsing neuromyelitis optica, using a time to first relapse study design.

• Aspirin for Treatment of Multiple Sclerosis-Related Fatigue Scottsdale/Phoenix, Ariz.

  The purpose of this study is to determine whether aspirin is effective for treatment of fatigue caused by multiple sclerosis (MS).

• Neuromyelitis Optica Clinical Consortium (NMOCC) Clinical Database Development for Neuromyelitis Optica Spectrum Disorders Scottsdale/Phoenix, Ariz.

  The primary objective is of this protocol to create a database of NMO patient information that can be queried to address specific scientific questions.  The first series of questions will focus on the clinical characteristics and course of the disease.  For example, sex ratio, ethnicity, and age of onset will be described for NMOSD as a whole and amongst the different diagnostic subcategories.  A main question of whether NMO-IgG seropositive patients differ with respect to disease activity compared with seronegative patients and exploratory multivariable analyses of the natural history will be conducted